Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse

Dale Schenk, Robin Barbour, Whitney Dunn, Grace Gordon, Henry Grajeda, Teresa Guldo, Kang Hu, Jiping Huang, Kelly Johnson-Wood, Karen Khan, Dora Kholodenko, Mike Lee, Zhenmei Liao, Ivan Lieberburg, Ruth Motter, Linda Mutter, Ferdie Soriano, George Shopp, Nicki Vasquez, Christopher VandevertShannan Walker, Mark Wogulis, Ted Yednock, Dora Games, Peter Seubert

Research output: Contribution to journalArticle

2741 Citations (Scopus)

Abstract

Amyloid-β peptide (Aβ) seems to have a central role in the neuropathology of Alzheimer's disease (AD). Familial forms of the disease have been linked to mutations in the amyloid precursor protein (APP) and the presenilin genes. Disease-linked mutations in these genes result in increased production of the 42-amino-acid form of the peptide (Aβ42), which is the predominant form found in the amyloid plaques of Alzheimer's disease. The PDAPP transgenic mouse, which overexpresses mutant human APP (in which the amino acid at position 717 is phenylalanine instead of the normal valine), progressively develops many of the neuropathological hallmarks of Alzheimer's disease in an age- and brain-region-dependent manner. In the present study, transgenic animals were immunized with Aβ42, either before the onset of AD-type neuropathologies (at 5 weeks of age) or at an older age (11 months), when amyloid-β deposition and several of the subsequent neuropathological changes were well established. We report the immunization of the young animals essentially prevented the development of β-amyloid-plaque formation, neuritic dystrophy and astrogliosis. Treatment of the older animals also markedly reduced the extent and progression of these AD-like neuropathologies. Our results raise the possibility that immunization with amyloid-β may be effective in preventing and treating Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)173-177
Number of pages5
JournalNature
Volume400
Issue number6740
DOIs
StatePublished - Jul 8 1999
Externally publishedYes

Fingerprint

Amyloid
Immunization
Alzheimer Disease
Pathology
Amyloid beta-Protein Precursor
Amyloid Plaques
Presenilins
Amino Acids
Mutation
Genetically Modified Animals
Valine
Phenylalanine
Transgenic Mice
Genes
Brain
Neuropathology

ASJC Scopus subject areas

  • General

Cite this

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guldo, T., ... Seubert, P. (1999). Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature, 400(6740), 173-177. https://doi.org/10.1038/22124

Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse. / Schenk, Dale; Barbour, Robin; Dunn, Whitney; Gordon, Grace; Grajeda, Henry; Guldo, Teresa; Hu, Kang; Huang, Jiping; Johnson-Wood, Kelly; Khan, Karen; Kholodenko, Dora; Lee, Mike; Liao, Zhenmei; Lieberburg, Ivan; Motter, Ruth; Mutter, Linda; Soriano, Ferdie; Shopp, George; Vasquez, Nicki; Vandevert, Christopher; Walker, Shannan; Wogulis, Mark; Yednock, Ted; Games, Dora; Seubert, Peter.

In: Nature, Vol. 400, No. 6740, 08.07.1999, p. 173-177.

Research output: Contribution to journalArticle

Schenk, D, Barbour, R, Dunn, W, Gordon, G, Grajeda, H, Guldo, T, Hu, K, Huang, J, Johnson-Wood, K, Khan, K, Kholodenko, D, Lee, M, Liao, Z, Lieberburg, I, Motter, R, Mutter, L, Soriano, F, Shopp, G, Vasquez, N, Vandevert, C, Walker, S, Wogulis, M, Yednock, T, Games, D & Seubert, P 1999, 'Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse', Nature, vol. 400, no. 6740, pp. 173-177. https://doi.org/10.1038/22124
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guldo T et al. Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature. 1999 Jul 8;400(6740):173-177. https://doi.org/10.1038/22124
Schenk, Dale ; Barbour, Robin ; Dunn, Whitney ; Gordon, Grace ; Grajeda, Henry ; Guldo, Teresa ; Hu, Kang ; Huang, Jiping ; Johnson-Wood, Kelly ; Khan, Karen ; Kholodenko, Dora ; Lee, Mike ; Liao, Zhenmei ; Lieberburg, Ivan ; Motter, Ruth ; Mutter, Linda ; Soriano, Ferdie ; Shopp, George ; Vasquez, Nicki ; Vandevert, Christopher ; Walker, Shannan ; Wogulis, Mark ; Yednock, Ted ; Games, Dora ; Seubert, Peter. / Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse. In: Nature. 1999 ; Vol. 400, No. 6740. pp. 173-177.
@article{b8583a1260ad4ecd84e4cfcbd0fb473b,
title = "Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse",
abstract = "Amyloid-β peptide (Aβ) seems to have a central role in the neuropathology of Alzheimer's disease (AD). Familial forms of the disease have been linked to mutations in the amyloid precursor protein (APP) and the presenilin genes. Disease-linked mutations in these genes result in increased production of the 42-amino-acid form of the peptide (Aβ42), which is the predominant form found in the amyloid plaques of Alzheimer's disease. The PDAPP transgenic mouse, which overexpresses mutant human APP (in which the amino acid at position 717 is phenylalanine instead of the normal valine), progressively develops many of the neuropathological hallmarks of Alzheimer's disease in an age- and brain-region-dependent manner. In the present study, transgenic animals were immunized with Aβ42, either before the onset of AD-type neuropathologies (at 5 weeks of age) or at an older age (11 months), when amyloid-β deposition and several of the subsequent neuropathological changes were well established. We report the immunization of the young animals essentially prevented the development of β-amyloid-plaque formation, neuritic dystrophy and astrogliosis. Treatment of the older animals also markedly reduced the extent and progression of these AD-like neuropathologies. Our results raise the possibility that immunization with amyloid-β may be effective in preventing and treating Alzheimer's disease.",
author = "Dale Schenk and Robin Barbour and Whitney Dunn and Grace Gordon and Henry Grajeda and Teresa Guldo and Kang Hu and Jiping Huang and Kelly Johnson-Wood and Karen Khan and Dora Kholodenko and Mike Lee and Zhenmei Liao and Ivan Lieberburg and Ruth Motter and Linda Mutter and Ferdie Soriano and George Shopp and Nicki Vasquez and Christopher Vandevert and Shannan Walker and Mark Wogulis and Ted Yednock and Dora Games and Peter Seubert",
year = "1999",
month = "7",
day = "8",
doi = "10.1038/22124",
language = "English (US)",
volume = "400",
pages = "173--177",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "6740",

}

TY - JOUR

T1 - Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse

AU - Schenk, Dale

AU - Barbour, Robin

AU - Dunn, Whitney

AU - Gordon, Grace

AU - Grajeda, Henry

AU - Guldo, Teresa

AU - Hu, Kang

AU - Huang, Jiping

AU - Johnson-Wood, Kelly

AU - Khan, Karen

AU - Kholodenko, Dora

AU - Lee, Mike

AU - Liao, Zhenmei

AU - Lieberburg, Ivan

AU - Motter, Ruth

AU - Mutter, Linda

AU - Soriano, Ferdie

AU - Shopp, George

AU - Vasquez, Nicki

AU - Vandevert, Christopher

AU - Walker, Shannan

AU - Wogulis, Mark

AU - Yednock, Ted

AU - Games, Dora

AU - Seubert, Peter

PY - 1999/7/8

Y1 - 1999/7/8

N2 - Amyloid-β peptide (Aβ) seems to have a central role in the neuropathology of Alzheimer's disease (AD). Familial forms of the disease have been linked to mutations in the amyloid precursor protein (APP) and the presenilin genes. Disease-linked mutations in these genes result in increased production of the 42-amino-acid form of the peptide (Aβ42), which is the predominant form found in the amyloid plaques of Alzheimer's disease. The PDAPP transgenic mouse, which overexpresses mutant human APP (in which the amino acid at position 717 is phenylalanine instead of the normal valine), progressively develops many of the neuropathological hallmarks of Alzheimer's disease in an age- and brain-region-dependent manner. In the present study, transgenic animals were immunized with Aβ42, either before the onset of AD-type neuropathologies (at 5 weeks of age) or at an older age (11 months), when amyloid-β deposition and several of the subsequent neuropathological changes were well established. We report the immunization of the young animals essentially prevented the development of β-amyloid-plaque formation, neuritic dystrophy and astrogliosis. Treatment of the older animals also markedly reduced the extent and progression of these AD-like neuropathologies. Our results raise the possibility that immunization with amyloid-β may be effective in preventing and treating Alzheimer's disease.

AB - Amyloid-β peptide (Aβ) seems to have a central role in the neuropathology of Alzheimer's disease (AD). Familial forms of the disease have been linked to mutations in the amyloid precursor protein (APP) and the presenilin genes. Disease-linked mutations in these genes result in increased production of the 42-amino-acid form of the peptide (Aβ42), which is the predominant form found in the amyloid plaques of Alzheimer's disease. The PDAPP transgenic mouse, which overexpresses mutant human APP (in which the amino acid at position 717 is phenylalanine instead of the normal valine), progressively develops many of the neuropathological hallmarks of Alzheimer's disease in an age- and brain-region-dependent manner. In the present study, transgenic animals were immunized with Aβ42, either before the onset of AD-type neuropathologies (at 5 weeks of age) or at an older age (11 months), when amyloid-β deposition and several of the subsequent neuropathological changes were well established. We report the immunization of the young animals essentially prevented the development of β-amyloid-plaque formation, neuritic dystrophy and astrogliosis. Treatment of the older animals also markedly reduced the extent and progression of these AD-like neuropathologies. Our results raise the possibility that immunization with amyloid-β may be effective in preventing and treating Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=0033536163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033536163&partnerID=8YFLogxK

U2 - 10.1038/22124

DO - 10.1038/22124

M3 - Article

C2 - 10408445

AN - SCOPUS:0033536163

VL - 400

SP - 173

EP - 177

JO - Nature

JF - Nature

SN - 0028-0836

IS - 6740

ER -